Does bitter melon contain an activator of AMP-activated kinase?

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 340-343

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; ENZYME ACTIVATOR; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIPID; LIVER ENZYME; METFORMIN; MOMORDICA CHARANTIA EXTRACT; PHENFORMIN;

AGING; CANCER PREVENTION; CELL MEMBRANE; CLINICAL TRIAL; DIABETES MELLITUS; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FRUIT; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; LIPID BLOOD LEVEL; LIVER; LIVER METABOLISM; MOMORDICA CHARANTIA; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REVIEW; RODENT; SKELETAL MUSCLE; WEIGHT GAIN;

CUCUMIS; MOMORDICA; MOMORDICA CHARANTIA; RODENTIA;

EID: 3242813810     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.01.041     Document Type: Article

References (49)

1. Virdi J., Sivakami S., Shahani S., Suthar A.C., Banavalikar M.M., Biyani M.K. Antihyperglycemic effects of three extracts from Momordica charantia. J. Ethnopharmacol. 88:2003;107-111
2. Sharma V.N., Sogani R.K., Arora R.B. Some observations on hypoglycaemia activity in Momordica charantia. Indian J. Med. Res. 48:1960;471
3. Leatherdale B.A., Panesar R.K., Singh G., Atkins T.W., Bailey C.J., Bignell A.H. Improvement in glucose tolerance due to Momordica charantia (karela). Br. Med. J. (Clin. Res. Ed.). 282:1981;1823-1824
4. Akhtar M.S. Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. J. Pak. Med. Assoc. 32:1982;106-107
5. Lei Q.J., Jiang X.M., Luo A.C., Liu Z.F., He X.C., Wang X.D., et al. Influence of balsam pear (the fruit of Momordica charantia L.) on blood sugar level. J. Tradit. Chin. Med. 5:1985;99-106
6. Welihinda J., Karunanayake E.H., Sheriff M.H., Jayasinghe K.S. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J. Ethnopharmacol. 17:1986;277-282
7. Ahmad N., Hassan M.R., Halder H., Bennoor K.S. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med. Res. Counc. Bull. 25:1999;11-13
8. Kameswararao B., Kesavulu M.M., Apparao C. Evaluation of antidiabetic effect of Momordica cymbalaria fruit in alloxan-diabetic rats. Fitoterapia. 74:2003;7-13
9. Welihinda J., Arvidson G., Gylfe E., Hellman B., Karlsson E. The insulin-releasing activity of the tropical plant Momordica charantia. Acta Biol. Med. Ger. 41:1982;1229-1240
10. Sitasawad S.L., Shewade Y., Bhonde R. Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J. Ethnopharmacol. 73:2000;71-79
11. Ahmed I., Adeghate E., Sharma A.K., Pallot D.J., Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res. Clin. Pract. 40:1998;145-151
12. Day C., Cartwright T., Provost J., Bailey C.J. Hypoglycaemic effect of Momordica charantia extracts. Planta Med. 56:1990;426-429
13. Sarkar S., Pranava M., Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol. Res. 33:1996;1-4
14. Miura T., Itoh C., Iwamoto N., Kato M., Kawai M., Park S.R., et al. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J. Nutr. Sci. Vitaminol. (Tokyo). 47:2001;340-344
15. Vikrant V., Grover J.K., Tandon N., Rathi S.S., Gupta N. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J. Ethnopharmacol. 76:2001;139-143
16. Chen Q., Chan L.L., Li E.T. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr. 133:2003;1088-1093
17. Khanna P., Jain S.C., Panagariya A., Dixit V.P. Hypoglycemic activity of polypeptide-p from a plant source. J. Nat. Prod. 44:1981;648-655
18. Ng T.B., Wong C.M., Li W.W., Yeung H.W. Acid-ethanol extractable compounds from fruits and seeds of the bitter gourd Momordica charantia: effects on lipid metabolism in isolated rat adipocytes. Am. J. Chin. Med. 15:1987;31-42
19. Matsuda H., Murakami T., Shimada H., Matsumura N., Yoshikawa M., Yamahara J. Inhibitory mechanisms of oleanolic acid 3-O-monodesmosides on glucose absorption in rats. Biol. Pharm. Bull. 20:1997;717-719
20. Matsuda H., Li Y., Murakami T., Matsumura N., Yamahara J., Yoshikawa M. Antidiabetic principles of natural medicines. III. Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Chem. Pharm. Bull. (Tokyo). 46:1998;1399-1403
21. Welihinda J., Karunanayake E.H. Extra-pancreatic effects of Momordica charantia in rats. J. Ethnopharmacol. 17:1986;247-255
22. Shibib B.A., Khan L.A., Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem. J. 292(Pt 1):1993;267-270
23. Rao B.K., Kesavulu M.M., Giri R., Appa R.C. Antidiabetic and hypolipidemic effects of Momordica cymbalaria hook. Fruit powder in alloxan-diabetic rats. J. Ethnopharmacol. 67:1999;103-109
24. Rathi S.S., Grover J.K., Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother. Res. 16:2002;236-243
25. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:2001;1167-1174
26. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51:2002;2074-2081
27. Hawley S.A., Gadalla A.E., Olsen G.S., Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2002;2420-2425
28. Mithieux G., Guignot L., Bordet J.C., Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes. 51:2002;139-143
29. Zheng D., MacLean P.S., Pohnert S.C., Knight J.B., Olson A.L., Winder W.W., et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol. 91:2001;1073-1083
30. Jessen N., Pold R., Buhl E.S., Jensen L.S., Schmitz O., Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J. Appl. Physiol. 94:2003;1373-1379
31. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:1995;550-554
32. Fontbonne A., Charles M.A., Juhan-Vague I., Bard J.M., Andre P., Isnard F., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 19:1996;920-926
33. Kay J.P., Alemzadeh R., Langley G., D'Angelo L., Smith P., Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 50:2001;1457-1461
34. Ahmed I., Lakhani M.S., Gillett M., John A., Raza H. Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 51:2001;155-161
35. Platel K., Shurpalekar K.S., Srinivasan K. Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung. 37:1993;156-160
36. Singh N., Tyagi S.D., Agarwal S.C. Effects of long term feeding of acetone extract of Momordica charantia (whole fruit powder) on alloxan diabetic albino rats. Indian J. Physiol. Pharmacol. 33:1989;97-100
37. Fanghanel G., Sanchez-Reyes L., Trujillo C., Sotres D., Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 19:1996;1185-1189
38. Guthrie R. Treatment of non-insulin-dependent diabetes mellitus with metformin. J. Am. Board Fam. Pract. 10:1997;213-221
39. Palumbo P.J. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications. 12:1998;110-119
40. Charles M.A., Eschwege E., Grandmottet P., Isnard F., Cohen J.M., Bensoussan J.L., et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab. Res. Rev. 16:2000;2-7
41. Ganguly C., De S., Das S. Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. Eur. J. Cancer Prev. 9:2000;283-288
42. Chiampanichayakul S., Kataoka K., Arimochi H., Thumvijit S., Kuwahara T., Nakayama H., et al. Inhibitory effects of bitter melon (Momordica charantia Linn.) on bacterial mutagenesis and aberrant crypt focus formation in the rat colon. J. Med. Invest. 48:2001;88-96
43. Nagasawa H., Watanabe K., Inatomi H. Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am. J. Chin. Med. 30:2002;195-205
44. Dilman V.M., Berstein L.M., Zabezhinski M.A., Alexandrov V.A., Bobrov J.F., Pliss G.B. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch. Geschwulstforsch. 48:1978;1-8
45. Dilman V.M., Anisimov V.N. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology. 26:1980;241-246
46. McCarty MF. Chronic activation of AMP-activated kinase as a strategy for slowing aging. Med Hypotheses 2004 [in press]
47. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:2002;393-403
48. Ruderman N.B., Cacicedo J.M., Itani S., Yagihashi N., Saha A.K., Ye J.M., et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans. 31:2003;202-206
49. Krentz A.J., Ferner R.E., Bailey C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11:1994;223-241